Helicobacter Pylori Clinical Trial
Official title:
A Retrospective Observational Real-world Study to Evaluate Diagnosis Pattern, Treatment Pattern and Effectiveness of Eradication Treatment in Helicobacter Pylori (H. Pylori) Patients in China
Verified date | April 2023 |
Source | Takeda |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The main aim of the study is to review treatment therapies in people with Helicobacter pylori (H. pylori) infections in standard hospital settings in China. In this study, the study doctors will review medical records of participants who have had H. pylori infections any time from 1st January 2019 to 31st December 2021. This study is about collecting existing data only; participants are not treated and do not need to visit a study doctor during this study.
Status | Completed |
Enrollment | 23000 |
Est. completion date | April 12, 2023 |
Est. primary completion date | April 12, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Participants with a record of H. pylori infection diagnosis or positive result of H. pylori diagnostic testing between 1st January 2019 and 31st December 2021. Exclusion Criteria: Not applicable. |
Country | Name | City | State |
---|---|---|---|
China | Army Medical Center of PLA | Chongqing | Sichuan |
China | Zhejiang Provincial Peoples Hospital | Hangzhou | Zhejiang |
China | Shandong Provincial Hospital Affiliated to Shandong First Medical University | Jinan | Shandong |
China | Shanghai Tenth Peoples Hospital | Shanghai | Shanghai |
China | Tianjin First Central Hospital | Tianjin | Tianjin |
Lead Sponsor | Collaborator |
---|---|
Takeda |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percentage of Each Eradication Regimen Initially Prescribed After Index Date | Eradication therapy in this study includes standard bismuth quadruple therapy, standard triple therapy, and dual therapy. Eradication therapy will be identified according to the combination of drugs that are prescribed on the same day. Index date will be defined as first diagnosis date or the first date of a positive result of H. pylori diagnostic testing whichever came first during the participant identification period. For the percentage calculation of each eradication regimen, the denominator is the total usage count of all standard eradication therapies taken by eligible participants and the numerator is the total usage count of each eradication therapy. | Up to 36 months | |
Secondary | Percentage of Each Eradication Therapy's Treatment Duration From the Date of Prescription Until the Termination | Duration of eradication therapy is defined as the days in a medication-taking interval, which is equal to dosage by unit. Eradication therapy in this study includes standard bismuth quadruple therapy, standard triple therapy, and dual therapy. The duration of eradication therapy will be categorized into categorical variables including 7 days, 10 days, 14 days, or others. For percentage calculation of treatment duration of each eradication therapy, the denominator is the total usage count of all eradication therapies taken by eligible participants and the numerator is the count of the categorized duration of each eradication therapy. | From date of prescription up to 14 days | |
Secondary | Percentage of Each Diagnostic Testing Used Before the Prescription of Eradication Therapy | H. pylori diagnostic testing includes non-invasive testing (urea breath testing [UBT], fecal antigen testing, serological testing) and invasive testing (polymerase chain reaction [PCR], culture, rapid urease test [RUT] and histology). For percentage calculation of each diagnosis before eradication therapy, the denominator is the total count of diagnostic testing and the numerator is the count of each type of diagnostic testing. | Up to 36 months | |
Secondary | Percentage of Each Efficacy Evaluation Testing After the Termination of Eradication Therapy | Efficacy evaluation testing is defined as H. pylori testing performed during the 28 days of efficacy evaluation period after treatment completion and this testing may extend to the follow-up period until observation period ends. For percentage calculation of efficacy evaluation testing after eradication therapy, the denominator is the total count of efficacy evaluation testing and the numerator is the count of each type of efficacy evaluation testing. | Up to 36 months | |
Secondary | Percentage of the Duration From the Termination of Eradication Therapy Until the Efficacy Evaluation Testing | The duration is defined as the time period between the last day of taking medication of eradication therapy and the day receiving efficacy evaluation testing. The duration of eradication therapy will be categorized into categorical variables including less than or equal to (<=) 4 weeks or greater than (>) 4 weeks. For percentage calculation of efficacy evaluation testing after each eradication therapy, the denominator is the total count of efficacy evaluation testing and the numerator is the count of duration (<=4 weeks or >4 weeks) . | Up to 36 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02892409 -
TAK-438 Bismuth Drug Interaction Study
|
Phase 1 | |
Completed |
NCT00596401 -
The Preventive Effect of Helicobacter Pylori Eradication on the Development of Gastric Cancer
|
||
Not yet recruiting |
NCT04101708 -
A Comparison of High-dose Dual Therapy and Half-dose Clarithromycin-containing Bismuth Quadruple Therapy for H.P Eradication in Elderly Patients
|
Phase 4 | |
Recruiting |
NCT04030715 -
The Associations Between the Gastric Mucosal Pathology and the Eradication Rate of H.Pylori :A Multicenter Study
|
N/A | |
Recruiting |
NCT04029415 -
The Study of the Antimicrobial Resistance of Helicobacter Pylori in Shandong Province
|
||
Recruiting |
NCT04029493 -
The Situation of Re-infection of Helicobacter Pylori After Successful Eradication
|
||
Not yet recruiting |
NCT02933229 -
The Influence of Helicobacter Pylori Eradication on Gastric Pathology: a Long-term, Prospective Cohort Study
|
Phase 4 | |
Not yet recruiting |
NCT02934048 -
Optimal Duration of Antimicrobial Susceptibility Test (AST) Guided Rescue Therapy for Helicobacter Pylori Infection
|
Phase 4 | |
Recruiting |
NCT05184491 -
Nitazoxanide and Lansoprazole Based Regimens for H. Pylori Management
|
Phase 4 | |
Recruiting |
NCT05790525 -
Effect of Oral Helicobacter Pylori Infection on the Efficacy of Gastroluminal Helicobacter Pylori Eradication Therapy
|
Phase 4 | |
Completed |
NCT05790512 -
Association of Oral Helicobacter Pylori Infection With Gastric Helicobacter Pylori Infection
|
||
Recruiting |
NCT05276557 -
PyloPlus Urea Breath Test System Pediatric Safety and Efficacy Study
|
Phase 3 | |
Recruiting |
NCT03177629 -
H. Pylori Eradication for Moderate ITP
|
Phase 3 | |
Recruiting |
NCT05053945 -
Helicobacter Pylori, Atrophic Gastritis and Intestinal Metaplasia Registry and Prospective Study
|
||
Recruiting |
NCT05449028 -
Helicobacter Pylori Eradication Therapy in Portugal
|
N/A | |
Recruiting |
NCT00306280 -
Feasibility Study of Phototherapy System to Treat H Pylori
|
N/A | |
Active, not recruiting |
NCT02675010 -
Value of Additional Corpus Biopsy for Diagnosis of H Pylori in Atrophic Gastritis. Prospective Non-randomized Study
|
N/A | |
Withdrawn |
NCT00467155 -
Helicobacter in The Gambia (Part 2)
|
N/A | |
Completed |
NCT03716622 -
A Comparison of Clarithromycin-based and Furazolidone-based Bismuth-containing Regimens for H. Pylori Eradication
|
Phase 4 | |
Not yet recruiting |
NCT04937426 -
Development of a Laboratory Test for the Detection of a Fluorescent-labeled Urease Inhibitor Marker Attached to Helicobacter Pylori
|
N/A |